Titan Pharmaceuticals Proposes Merger with TalenTec
Deal News | Jun 03, 2025 | Globenewswire
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) has announced the filing of a registration statement on Form F-4 with the U.S. Securities and Exchange Commission by Black Titan Corporation for a proposed business combination with TalenTec Sdn. Bhd. The companies have already entered into a Merger Agreement, with Titan anticipated to be combined with TalenTec in a reverse merger transaction. The registration statement, which contains a preliminary proxy statement/prospectus, has not yet been declared effective by the SEC. Approval by Titan shareholders and satisfaction of other customary closing conditions are required for the Business Combination to occur, which is expected to close in the third quarter of 2025. The companies involved have been working towards creating a combined entity under the holding of Black Titan Corporation, and once effective, a definitive Proxy Statement/Prospectus will be mailed to Titan's shareholders.
Sectors
- Pharmaceuticals
- Mergers and Acquisitions
Geography
- United States – Titan Pharmaceuticals is based in New York, and the filing was made with the U.S. SEC.
- Malaysia – TalenTec Sdn. Bhd., formerly known as KE Sdn. Bhd., is a company based in Malaysia.
Industry
- Pharmaceuticals – Titan Pharmaceuticals operates in the pharmaceutical industry, developing and commercializing pharmaceutical products.
- Mergers and Acquisitions – The article discusses a business transaction involving a merger, reflecting strategic M&A activities within the industry.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Titan Pharmaceuticals, Inc. | Target Company | Company | A publicly traded pharmaceutical company operating under NASDAQ: TTNP. |
| TalenTec Sdn. Bhd. | Bidding Company | Company | Malaysian company entering into a business combination with Titan Pharmaceuticals. |
| Black Titan Corporation | Holding Company | Company | The entity under which the merger between Titan Pharmaceuticals and TalenTec will occur. |
| Chay Weei Jye | Chief Executive Officer | Person | CEO involved in the announcement of the merger proposal. |